KR960034205A - 피페리딘 유도체와 그것의 제조방법 및 치료적 이용 - Google Patents

피페리딘 유도체와 그것의 제조방법 및 치료적 이용 Download PDF

Info

Publication number
KR960034205A
KR960034205A KR1019960006462A KR19960006462A KR960034205A KR 960034205 A KR960034205 A KR 960034205A KR 1019960006462 A KR1019960006462 A KR 1019960006462A KR 19960006462 A KR19960006462 A KR 19960006462A KR 960034205 A KR960034205 A KR 960034205A
Authority
KR
South Korea
Prior art keywords
methyl
formula
group
atom
compound
Prior art date
Application number
KR1019960006462A
Other languages
English (en)
Inventor
에방 룩
제강 사미르
데포스 제라르
알레뜨뤼 미쉘
Original Assignee
에.뚜레 레메뜨르
신떼라도 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에.뚜레 레메뜨르, 신떼라도 소시에떼 아노님 filed Critical 에.뚜레 레메뜨르
Publication of KR960034205A publication Critical patent/KR960034205A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

다음 일반식(Ⅰ)의 피페리딘 유도체 및 그것의 치료적 이용.
[식에서, X는 산소원자 또는 메틸렌기를 나타내고, R1은 염소원자, 플루오르원자, 메틸기, 메톡시기 또는 아미노기를 나타내고, R2및 R3은 서로 독립적으로 수소원자 또는 메틸기를 나타낸다.]

Description

피페리딘 유도체와 그것의 제조방법 및 치료적 이용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 순수한 거울상 이성질체 또는 라세미 혼합물을 포함한 거울상 이성질체의 혼합물 형태의 다음 일반식(Ⅰ)의 피페리딘 유도체 및 그 약학적으로 허용되는 산과의 부과염.
    [식에서, X는 산소원자 또는 메틸렌기를 나타내고, R1은 염소원자, 플루오르원자, 메틸기, 메톡시기 또는 아미노기를 나타내고, R2및 R3은 서로 독립적으로 수소원자 또는 메틸기를 나타낸다.]
  2. 제1항에 있어서, X가 산소원자를 나타내고 R1이 고리상의 위치 8에 있는 것을 특징으로 하는 유도체.
  3. (S)-8-플루오로-4-메틸-2-[4-(5-메틸-1H-이미다졸-4-일) 피페리딘-1-일]-4,5-디히드로이미다조[1,5,4-de][1,4]벤조옥사진 및 그 약학적으로 허용되는 산과의 부가염.
  4. (S)-8-플루오로-4-메틸-2-[4-(1H-이미다졸-4-일) 피페리딘-1-일]-4,5-디히드로이미다조[1,5,4-de][1,4]벤조옥사진 및 그 약학적으로 허용되는 산과의 부가염.
  5. 제1항에 따른 식(Ⅰ)의 화합물의 제조방법에 있어서, X, R1및 R2가 제1항과 같이 정의되고 Y가 할로겐원자, 특히 염소원자를 나타내는 식(Ⅱ)
    의 화합물을 R3이 제1항과 같이 정의되는 식(Ⅲ)
    의 화합물과 반응시키는 것을 특징으로 하는 제조방법.
  6. 제1항 내지 제4항 중의 어느 한 항에 따른 식(Ⅰ)의 화합물을 함유하는 것을 특징으로 하는 의약.
  7. 제1항 내지 제4항 중의 어느 한 항에 따른 식(Ⅰ)의 화합물을 적당한 부형제와 조합하여 구성되는 것을 특징으로 하는 의약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960006462A 1995-03-13 1996-03-12 피페리딘 유도체와 그것의 제조방법 및 치료적 이용 KR960034205A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502863 1995-03-13
FR9502863A FR2731708B1 (fr) 1995-03-13 1995-03-13 Derives de piperidine, leur procede de preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
KR960034205A true KR960034205A (ko) 1996-10-22

Family

ID=9476960

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960006462A KR960034205A (ko) 1995-03-13 1996-03-12 피페리딘 유도체와 그것의 제조방법 및 치료적 이용

Country Status (15)

Country Link
EP (1) EP0732334A1 (ko)
JP (1) JPH08269058A (ko)
KR (1) KR960034205A (ko)
CN (1) CN1140174A (ko)
AU (1) AU4800896A (ko)
CA (1) CA2171579A1 (ko)
CZ (1) CZ75496A3 (ko)
FR (1) FR2731708B1 (ko)
HU (1) HUP9600624A2 (ko)
IL (1) IL117455A0 (ko)
NO (1) NO961000L (ko)
NZ (1) NZ286164A (ko)
PL (1) PL313204A1 (ko)
SK (1) SK34196A3 (ko)
ZA (1) ZA961994B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191106T3 (es) * 1995-09-18 2003-09-01 Glaxo Group Ltd Uso de ondansetron en la fabricacion de un medicamento para el tratamiento del temblor.
TW527186B (en) 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
FR2801589A1 (fr) * 1999-11-25 2001-06-01 Sanofi Synthelabo Derives de 2-arylquinoleine, leur preparation et leur application en therapeutique
CA2412368A1 (fr) 2000-08-08 2002-02-14 Sanofi-Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816619B1 (fr) * 2000-11-15 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816941B1 (fr) * 2000-11-23 2003-01-31 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
TWI719464B (zh) 2013-03-15 2021-02-21 美商英塞特控股公司 作為bet蛋白抑制劑之三環雜環
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
DK3674302T3 (da) 2014-04-23 2023-04-03 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
KR20210025016A (ko) * 2018-06-28 2021-03-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674855B1 (fr) * 1991-04-03 1994-01-14 Synthelabo Derives de piperidine, leur preparation et leur application en therapeutique.
FR2696176B1 (fr) * 1992-09-28 1994-11-10 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
FR2710915B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.

Also Published As

Publication number Publication date
CA2171579A1 (en) 1996-09-14
PL313204A1 (en) 1996-09-16
NZ286164A (en) 1996-11-26
CZ75496A3 (en) 1996-10-16
FR2731708B1 (fr) 1997-04-30
NO961000D0 (no) 1996-03-12
CN1140174A (zh) 1997-01-15
IL117455A0 (en) 1996-07-23
NO961000L (no) 1996-09-16
SK34196A3 (en) 1996-10-02
JPH08269058A (ja) 1996-10-15
HU9600624D0 (en) 1996-05-28
AU4800896A (en) 1996-09-26
FR2731708A1 (fr) 1996-09-20
ZA961994B (en) 1996-09-03
HUP9600624A2 (en) 1997-01-28
EP0732334A1 (fr) 1996-09-18

Similar Documents

Publication Publication Date Title
KR960034205A (ko) 피페리딘 유도체와 그것의 제조방법 및 치료적 이용
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
ATE22889T1 (de) 8-chlor-1,5-benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
DE68901153D1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AU7215987A (en) 1,4-disubstituted piperazine derivatives, pharmaceutical compositions containing them and process for preparing same
DK96786A (da) Aminosyrederivater
KR870008842A (ko) N-[2-{[(2- 히드록시 페닐)(페닐)메틸렌]아미노}에틸]아세트아미드 유도체, 그의 제법 및 치료에의 응용
DE69110828D1 (de) Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
DE69206787D1 (de) 4-[(2-Benzothiazolyl)Methylamino]-alpha-(3,4-Difluorphenoxy)methyl-1-piperidenethanol
DE3876711D1 (de) Piperidin-derivate, deren herstellung und deren verwendung als heilmittel.
KR960017669A (ko) 양쪽성 3환식 화합물
AU658175B2 (en) Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
ATE73767T1 (de) Fluorine enthaltende vitamin-d3-derivate und verfahren zu ihrer herstellung.
DE3767533D1 (de) D-nor-7-ergolinderivate, verfahren zu ihrer herstellung, pharmazeutische zubereitung und verwendung.
KR920002614A (ko) 광학적 활성 티아제토퀴놀린-3-카르복실산 화합물, 그의 제조 방법 및 그를 함유한 제약학적 조성물
ATE243219T1 (de) 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin
ATE117682T1 (de) Substituierte benzothiazolinone, ihre herstellung und sie enthaltende pharmazeutische zusammenstellungen.
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
PT86422A (fr) Procede de preparation de derives d:acide dibenzo]be"-oxepine-acetique et de compositions pharmaceutiques les contenant
KR870700636A (ko) 고혈압 치료제 이를 함유하는 약제학적 조성물 및 고혈압 치료제 및 조성물을 제조하는 방법
RU96104655A (ru) Производные пиперидина, способ их изготовления и их применение в терапии

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid